首頁 > 市場調查報告書 > 醫療設備

手術用器具

市場調查報告書

商品編碼

1345421

全球心臟手術設備市場 - 2023-2030

Global Cardiac Surgery Devices Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

全球心臟手術器械市場將於 2022 年達到 21 億美元，預計到 2030 年將達到 32 億美元，2023-2030 年預測期間年複合成長率為 3.4%。

心臟手術設備用於治療許多心血管疾病，包括先天性心臟病、心律失常和心臟瓣膜疾病。心臟手術設備有助於治療心臟循環系統的結構問題，包括受損或堵塞的瓣膜和動脈。

近年來，由於起搏器、植入式心律轉復除顫器(ICD)、心臟瓣膜、球囊導管和支架等心臟和血管手術設備的使用，全球心臟手術設備市場出現了顯著成長，因為它們在管理心臟疾病方面發揮著關鍵作用。以及治療心血管疾病。

此外，技術進步的不斷進步、產品的推出和優惠的報銷政策等重要的成長動力將推動未來的市場成長。 Medtronic plc、Terumo Corporation、LivaNova Plc.、Abbott Laboratories、Murray Surgical Limited、Boston Scientific Corporation 等重要參與者都在市場上積極營運。

動力學

心臟手術設備的技術進步

心臟手術器械用於治療多種心血管疾病，如缺血性心臟病、風濕性心臟病、充血性心力衰竭、瓣膜性心臟病等。大公司的重大技術進步有助於推動市場成長。這些有效的進步有助於將研究發現轉化為新的治療方法，並改善對數百萬心臟病患者的護理。

例如，2023 年 5 月，Robocath 在 EuroPCR 2023 會議上推出了一款名為 R-One+ 的心臟手術機器人系統，用于冠狀動脈血管成形術。該平台允許心臟病專家通過位於導管實驗室的控制命令單元控制設備。

此外，雅培實驗室於 2022 年 12 月推出了最新一代經導管主動脈瓣植入 (TAVI) 系統 Navitor，為手術風險較高或極高的嚴重主動脈瓣狹窄患者提供微創設備。因此，由於上述因素，預計市場在預測期內將會提振。

有利的報銷政策正在提振心臟手術器械市場

報銷政策通常會考慮手術的複雜性、使用的導管類型以及手術期間使用的相關醫療資源等因素。報銷政策在心臟手術設備市場中發揮著至關重要的作用，因為它們決定了為執行心導管插入術的醫療保健提供者提供的承保範圍和財務報銷水平。

例如，據 Shockwave Medical 2022 年 7 月報導，自 2021 年初推出冠狀動脈 IVL 以來，Shockwave 在報銷方面取得了深入而重大的進展。他們在門診、ASC 和住院機構都有報銷。此外，還有機會通過冠狀動脈 III 類 CPT 代碼獲得醫生報銷。

心導管插入術的併發症將阻礙市場的成長

心導管插入術涉及將導管插入血管，這可能會導致血管損傷。這可能包括血管穿孔、剝離（血管壁撕裂）或破裂。血管損傷可能導致出血、血腫形成，甚至需要手術修復。

根據心血管組織 2023 年 4 月的報告，與心導管插入術相關的最常見風險是出血。在手術過程中，會做一個小切口來插入導管，這可能會導致出血。心導管插入術期間或之後可能會發生稱為心律失常的心律異常。這些可能是由於手術過程中血流的變化或導管與心肌的摩擦造成的。

Overview

Global Cardiac Surgery Devices Market reached US$ 2.1 billion in 2022 and is expected to reach US$ 3.2 billion by 2030 growing with a CAGR of 3.4% during the forecast period 2023-2030.

Cardiac surgery devices are used in the treatment of many cardiovascular diseases including congenital heart disease, arrhythmias, and heart valve disease. Cardiac surgery devices aid in the healing of structural problems in the circulatory system of the heart including damaged or clogged valves and arteries.

The global cardiac surgery devices market has witnessed significant growth in recent years due to the usage of cardiac and vascular surgery devices such as pacemakers, implantable cardioverter defibrillators (ICDs), heart valves, balloon catheters, and stents as they play a key role in managing and treating cardiovascular diseases.

Furthermore, significant growth drivers such as increasing technological advancements, product launches, and favorable reimbursement policies give rise to future market growth. Significant key players like Medtronic plc, Terumo Corporation, LivaNova Plc., Abbott Laboratories, Murray Surgical Limited, Boston Scientific Corporation, and others are actively operating in the market.

Dynamics

Technological Advancements in Cardiac Surgery Devices

Cardiac surgery devices are used to treat many cardiovascular diseases such as ischemic heart disease, rheumatic heart disease, congestive heart failure, and valvular heart disease. The major technological advancements by major companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with heart diseases.

For instance, in May 2023, Robocath launched a robot system for heart surgery called R-One+, for coronary angioplasties at the EuroPCR 2023 conference. The platform allows the cardiologist to control devices from the control command unit which can be positioned in the catheterization laboratory.

Additionally, in December 2022, Abbott Laboratories launched its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor, by making the minimally invasive device available for people with severe aortic stenosis who are at high or extreme surgical risk. Hence, due to the above factors, the market is expected to boost over the forecast period.

Favorable Reimbursement Policies are Boosting the Cardiac Surgery Device Market

Reimbursement policies often consider factors such as the complexity of the procedure, the type of catheter used, and the associated healthcare resources utilized during the procedure. Reimbursement policies play a crucial role in the cardiac surgery device market as they determine the level of coverage and financial reimbursement provided to healthcare providers for performing cardiac catheterization procedures.

For instance, according to Shockwave Medical July 2022, since the launch of Coronary IVL in early 2021, Shockwave has made deep and significant progress on reimbursement. They have reimbursement in the outpatient, ASC, and inpatient settings. In addition, an opportunity for physician reimbursement via Coronary Category III CPT code.

Complications for Cardiac Catheterization Will Hamper the Growth of the Market

Cardiac catheterization involves the insertion of a catheter into blood vessels, which can potentially cause vessel damage. This can include vessel perforation, dissection (tearing of the vessel wall), or rupture. Vessel damage can result in bleeding, hematoma formation, or even require surgical repair.

According to CardioVascular Group, April 2023, the most common risk associated with cardiac catheterization is bleeding. During the procedure, a small incision is made to insert the catheter, and this can lead to bleeding. Heart rhythm abnormalities called arrhythmias can happen during or after cardiac catheterization. These can result from changes in blood flow during the procedure or from the catheter rubbing against the heart muscle.

Segment Analysis

The global cardiac surgery devices market is segmented based on product, procedure, application, end users, and region.

Catheters from the Product Segment Accounted for Approximately 47.2% of the Global Cardiac Surgery Devices Market Share

The catheterization procedure is typically carried out in patients by using various catheters with certain congenital heart defects, such as transposition of the great arteries or pulmonary atresia, where there is an abnormal communication or inadequate blood flow between the atria. The demand for catheters is driven by the increasing incidence of cardiovascular diseases.

For instance, in May 2023, Abbott Laboratories received the approval of the U.S. Food and Drug Administration (FDA) for the company's TactiFlex Ablation Catheter which is sensor-enabled and the world's first ablation catheter with a flexible tip and contact force technology.

Additionally, in May 2022, Medtronic Plc. received approval from the U.S. Food and Drug Administration (FDA) for the IN.PACT 018 Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, a drug-coated balloon (DCB), indicated for the interventional treatment of peripheral arterial disease (PAD) in the superficial femoral and popliteal arteries.

Geographical Penetration

North America Accounted for Approximately 38.5% of the Market Share in 2022

North America has maintained a significant proportion of the cardiac surgery devices market in recent years, and this trend is anticipated to continue throughout the forecast period due to factors such as the rising number of open heart surgeries performed in the U.S. and technological advancements in cardiac surgery devices.

For instance, according to the Lifespan Health System, there are about 500,000 open heart surgeries performed each year in the United States. It is most often used for complicated procedures, such as coronary artery bypass, or complex procedures to the aorta or the heart itself. Also, coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021.

Competitive Landscape

The major global players in the market include: Medtronic Plc., Terumo Corporation, LivaNova Plc., Abbott Laboratories, Murray Surgical Limited, Boston Scientific Corporation, Getinge AB, Wexler Surgical, Lepu Medical Technology Co. Ltd, and Gore Medical Inc. among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the cardiac surgery device market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, device implantations, and consultations worldwide. Many hospitals are focused on COVID-19 cases, and this reduced cardiac surgery in many patients suffering from congenital heart defects.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the cardiac surgery device market is expected to be moderately affected over the forecast period.

By Product

Beating Heart Surgery Systems
- Stabilizers
- Positioners

Cardiopulmonary Bypass Equipment
- Arterial cannula
- Venous cannula
- Oxygenators

Catheters
- Balloon catheter
- Ablation Catheter
- Drainage Catheter

Perfusion Disposables
- Arterial Filters
- Connectors
- Hemoconcentrator

Others

By Procedure

Coronary Artery Bypass Grafting
Minimally Invasive Surgery
Others

By Application

Congenital Heart Disease
Coronary Artery Disease
Arrhythmias
Heart Valve Disease
Rheumatic Heart Disease
Aortic Aneurysm
Congestive Heart Failure
Others

By End Users

Hospital
Cardiac Centers
Ambulatory Surgical Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In March 2023, Shockwave Medical launched the new peripheral IVL catheter. The Shockwave L6 catheter is purpose-built to modify calcification in otherwise difficult-to-treat lesions in large peripheral vessels, including the iliac and the common femoral arteries.
In June 2023, Terumo Aortic launched of the company's global post-approval study (PAS) known as EXTEND for Thoraflex Hybrid, the only frozen elephant trunk (FET) device approved by the US Food and Drug Administration (FDA) for the treatment of patients with complex aortic arch disease.

Why Purchase the Report?

To visualize the global cardiac surgery devices market segmentation based on product, procedure, application, end users, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of global cardiac surgery devices market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global cardiac surgery devices market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Procedure
3.3. Snippet by Applications
3.4. Snippet by End Users
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Technological advancements in cardiac surgery devices
  - 4.1.1.2. Favorable reimbursement policies
- 4.1.2. Restraints
  - 4.1.2.1. Complications for cardiac catheterization
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
5.5. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Beating Heart Surgery System
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.2.3. Stabilizers
- 7.2.4. Positioners
7.3. Cardiopulmonary Bypass Equipment
- 7.3.1. Arterial cannula
- 7.3.2. Venous cannula
- 7.3.3. Oxygenators
7.4. Catheters
- 7.4.1. Balloon catheter
- 7.4.2. Ablation Catheter
- 7.4.3. Drainage Catheter
7.5. Perfusion Disposables
- 7.5.1. Arterial Filters
- 7.5.2. Connectors
- 7.5.3. Hemoconcentrator

8. By Procedure

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
- 8.1.2. Market Attractiveness Index, By Procedure
8.2. Coronary Artery Bypass Grafting
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Minimally Invasive Surgery
8.4. Others

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Congenital Heart Disease
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Coronary Artery Disease
9.4. Arrhythmias
9.5. Heart Valve Disease
9.6. Others

10. By End Users

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
- 10.1.2. Market Attractiveness Index, By End Users
10.2. Hospitals
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cardiac Centers
10.4. Ambulatory Surgical Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
- 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
- 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
- 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
- 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
- 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Procedure
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. Company Profiles

13.1. Medtronic Plc*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Terumo Corporation
13.3. LivaNova Plc
13.4. Abbott Laboratories
13.5. Murray Surgical Limited
13.6. Boston Scientific Corporation
13.7. Getinge AB
13.8. Wexler Surgical
13.9. Lepu Medical Technology Co. Ltd.
13.10. Gore Medical Inc.

LIST NOT EXHAUSTIVE